Impel Pharmaceuticals Inc. (IMPL) Stock

About Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Impel Pharmaceuticals Inc. is headquartered in US.

Impel Pharmaceuticals Inc. (IMPL) stock trades at $0.04 with a market capitalization of $956000. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of -0.02, price-to-sales of 0.08. Over the past 52 weeks the stock has ranged between $0.02 and $4.20, and currently trades 99.0% below its 52-week high.

On profitability, Impel Pharmaceuticals Inc. generates a return on equity (ROE) of 293.18% — well above the market average, a sign of a high-quality business, return on capital employed of -125.30%, an operating margin of -657.48%, a net profit margin of -992.31%.

Official website: impelpharma.com